Cytology specimens could serve as a reliable source for CLDN18.2 biomarker testing when interpreted at the threshold of 75% or above. Although discrepancies occur in some cases, the findings support the incorporation of cytology into biomarker testing workflows to expand access to CLDN18.2-targeted therapies for patients lacking surgical specimens.
Yang et al. (Wed,) studied this question.